Proposed Federal Bill H.R. 10336: What It Means for Supplement Access and Ingredient Innovation
A major new piece of federal legislation introduced in Congress could fundamentally change how dietary supplements are defined and regulated in the United States. Representative Diana Harshbarger (R-TN) introduced House Resolution 10336, titled the Dietary Supplement Innovation Act, aiming to resolve long-standing regulatory friction between pharmaceutical developers and natural supplement makers.
Here is an in-depth breakdown of H.R. 10336, how it alters the historic Dietary Supplement Health and Education Act (DSHEA) of 1994, and what natural health consumers need to understand.
Understanding the Drug Preclusion Clause
Under current federal law—specifically Section 301(ll) of the Food, Drug, and Cosmetic Act—if a natural compound or botanical ingredient becomes the subject of substantial clinical drug investigations or receives FDA drug approval, it can be legally precluded from being sold as a dietary supplement.
This rule was originally intended to prevent drug companies from repackaging prescription medications as over-the-counter supplements. However, in practice, it has created immense regulatory uncertainty. Natural ingredients that have been used safely for decades can suddenly face legal bans if a pharmaceutical company initiates clinical research on a synthesized version of the same compound.
Key Changes Introduced by H.R. 10336
H.R. 10336 proposes several specific amendments designed to modernize the drug preclusion framework:
- The Seven-Year Inactive Clause Under proposed rules, if a pharmaceutical sponsor halts Phase 2 or Phase 3 clinical trials on an ingredient for a continuous period of seven years (or publicly abandons development), the ingredient is freed from drug preclusion, allowing supplement manufacturers to use it legally.
- Firm Grandfathering Dates The bill establishes a firm date of October 15, 1994, explicitly grandfathering any natural substance or food ingredient marketed prior to that date.
- Specific Trial Triggers The bill replaces vague references to substantial clinical investigations with specific Phase 2 or Phase 3 clinical trial disclosures, creating a clear timeline for when preclusion begins.
- Expanded Judicial Review H.R. 10336 makes FDA warning letters asserting drug preclusion violations immediately reviewable in federal court, giving supplement makers a faster legal pathway to challenge regulatory administrative orders.
Debate Across the Natural Health Industry
The response to H.R. 10336 within the natural health community highlights two distinct perspectives:
Support from Trade Groups: Organizations like the Council for Responsible Nutrition (CRN), the Consumer Healthcare Products Association (CHPA), and the American Herbal Products Association (AHPA) praised the bill. They argue that ending perpetual pharmaceutical gatekeeping provides much-needed regulatory clarity and protects consumer access to innovative ingredients.
Concerns Over Gatekeeping: Conversely, Daniel Fabricant, president of the Natural Products Association (NPA), expressed concern that codifying clinical trial milestones could permanently solidify pharmaceutical priority rights over natural botanicals. Fabricant cautioned that forcing supplement companies into legal battles over market-entry dates could create new administrative barriers.
What This Means for Consumers
While H.R. 10336 moves through Congressional committees, dietary supplement consumers should remain observant. Regulatory clarity helps ensure that high-quality, research-backed natural compounds remain accessible without sudden administrative bans.
As always, choosing supplement brands that prioritize full label transparency, independent laboratory testing, and clean manufacturing practice remains the best way to safeguard your daily wellness routine.
